Stockreport

France Grants Reimbursed Compassionate Access (AAC) for Agenus’ BOT/BAL in Refractory MSS Metastatic Colorectal Cancer

Agenus Inc.  (AGEN) 
Last agenus inc. earnings: 3/12 07:30 am Check Earnings Report
US:NASDAQ Investor Relations: agenusbio.com/investors
PDF LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology, today announced its investigational combination botensilimab plus balstil [Read more]